A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy

C. Zhao, X. Chen, D. Zang, X. Lan, S. Liao, C. Yang, P. Zhang, J. Wu, X. Li, N. Liu, Y. Liao, H. Huang, X. Shi, L. Jiang, X. Liu, Z. He, Q. P. Dou, X. Wang, J. Liu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Based on the central role of the ubiquitin-proteasome system (UPS) in the degradation of cellular proteins, proteasome inhibition has been considered an attractive approach for anticancer therapy. Deubiquitinases (DUBs) remove ubiquitin conjugates from diverse substrates; therefore, they are essential regulators of the UPS. DUB inhibitors, especially the inhibitors of proteasomal DUBs are becoming a research hotspot in targeted cancer therapy. Previous studies have shown that metal complexes, such as copper and zinc complexes, can induce cancer cell apoptosis through inhibiting UPS function. Moreover, we have found that copper pyrithione inhibits both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that of the classical 20S proteasome inhibitor bortezomib. In the present study, we reveal that (i) nickel pyrithione complex (NiPT) potently inhibits the UPS via targeting the 19S proteasome-associated DUBs (UCHL5 and USP14), without effecting on the 20S proteasome; (ii) NiPT selectively induces proteasome inhibition and apoptosis in cultured tumor cells and cancer cells from acute myeloid leukemia human patients; and (iii) NiPT inhibits proteasome function and tumor growth in nude mice. This study, for the first time, uncovers a nickel complex as an effective inhibitor of the 19S proteasomal DUBs and suggests a potentially new strategy for cancer treatment.

Original languageEnglish (US)
Pages (from-to)5916-5927
Number of pages12
JournalOncogene
Volume35
Issue number45
DOIs
StatePublished - Nov 10 2016

Fingerprint

Proteasome Endopeptidase Complex
Nickel
Ubiquitin
Neoplasms
Therapeutics
Deubiquitinating Enzymes
Apoptosis
Cultured Tumor Cells
Proteasome Inhibitors
Coordination Complexes
Acute Myeloid Leukemia
Nude Mice
Proteolysis
Zinc
Copper

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., ... Liu, J. (2016). A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene, 35(45), 5916-5927. https://doi.org/10.1038/onc.2016.114

A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. / Zhao, C.; Chen, X.; Zang, D.; Lan, X.; Liao, S.; Yang, C.; Zhang, P.; Wu, J.; Li, X.; Liu, N.; Liao, Y.; Huang, H.; Shi, X.; Jiang, L.; Liu, X.; He, Z.; Dou, Q. P.; Wang, X.; Liu, J.

In: Oncogene, Vol. 35, No. 45, 10.11.2016, p. 5916-5927.

Research output: Contribution to journalArticle

Zhao, C, Chen, X, Zang, D, Lan, X, Liao, S, Yang, C, Zhang, P, Wu, J, Li, X, Liu, N, Liao, Y, Huang, H, Shi, X, Jiang, L, Liu, X, He, Z, Dou, QP, Wang, X & Liu, J 2016, 'A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy', Oncogene, vol. 35, no. 45, pp. 5916-5927. https://doi.org/10.1038/onc.2016.114
Zhao, C. ; Chen, X. ; Zang, D. ; Lan, X. ; Liao, S. ; Yang, C. ; Zhang, P. ; Wu, J. ; Li, X. ; Liu, N. ; Liao, Y. ; Huang, H. ; Shi, X. ; Jiang, L. ; Liu, X. ; He, Z. ; Dou, Q. P. ; Wang, X. ; Liu, J. / A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. In: Oncogene. 2016 ; Vol. 35, No. 45. pp. 5916-5927.
@article{95cb1b69866845998d02699357fe5f07,
title = "A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy",
abstract = "Based on the central role of the ubiquitin-proteasome system (UPS) in the degradation of cellular proteins, proteasome inhibition has been considered an attractive approach for anticancer therapy. Deubiquitinases (DUBs) remove ubiquitin conjugates from diverse substrates; therefore, they are essential regulators of the UPS. DUB inhibitors, especially the inhibitors of proteasomal DUBs are becoming a research hotspot in targeted cancer therapy. Previous studies have shown that metal complexes, such as copper and zinc complexes, can induce cancer cell apoptosis through inhibiting UPS function. Moreover, we have found that copper pyrithione inhibits both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that of the classical 20S proteasome inhibitor bortezomib. In the present study, we reveal that (i) nickel pyrithione complex (NiPT) potently inhibits the UPS via targeting the 19S proteasome-associated DUBs (UCHL5 and USP14), without effecting on the 20S proteasome; (ii) NiPT selectively induces proteasome inhibition and apoptosis in cultured tumor cells and cancer cells from acute myeloid leukemia human patients; and (iii) NiPT inhibits proteasome function and tumor growth in nude mice. This study, for the first time, uncovers a nickel complex as an effective inhibitor of the 19S proteasomal DUBs and suggests a potentially new strategy for cancer treatment.",
author = "C. Zhao and X. Chen and D. Zang and X. Lan and S. Liao and C. Yang and P. Zhang and J. Wu and X. Li and N. Liu and Y. Liao and H. Huang and X. Shi and L. Jiang and X. Liu and Z. He and Dou, {Q. P.} and X. Wang and J. Liu",
year = "2016",
month = "11",
day = "10",
doi = "10.1038/onc.2016.114",
language = "English (US)",
volume = "35",
pages = "5916--5927",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "45",

}

TY - JOUR

T1 - A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy

AU - Zhao, C.

AU - Chen, X.

AU - Zang, D.

AU - Lan, X.

AU - Liao, S.

AU - Yang, C.

AU - Zhang, P.

AU - Wu, J.

AU - Li, X.

AU - Liu, N.

AU - Liao, Y.

AU - Huang, H.

AU - Shi, X.

AU - Jiang, L.

AU - Liu, X.

AU - He, Z.

AU - Dou, Q. P.

AU - Wang, X.

AU - Liu, J.

PY - 2016/11/10

Y1 - 2016/11/10

N2 - Based on the central role of the ubiquitin-proteasome system (UPS) in the degradation of cellular proteins, proteasome inhibition has been considered an attractive approach for anticancer therapy. Deubiquitinases (DUBs) remove ubiquitin conjugates from diverse substrates; therefore, they are essential regulators of the UPS. DUB inhibitors, especially the inhibitors of proteasomal DUBs are becoming a research hotspot in targeted cancer therapy. Previous studies have shown that metal complexes, such as copper and zinc complexes, can induce cancer cell apoptosis through inhibiting UPS function. Moreover, we have found that copper pyrithione inhibits both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that of the classical 20S proteasome inhibitor bortezomib. In the present study, we reveal that (i) nickel pyrithione complex (NiPT) potently inhibits the UPS via targeting the 19S proteasome-associated DUBs (UCHL5 and USP14), without effecting on the 20S proteasome; (ii) NiPT selectively induces proteasome inhibition and apoptosis in cultured tumor cells and cancer cells from acute myeloid leukemia human patients; and (iii) NiPT inhibits proteasome function and tumor growth in nude mice. This study, for the first time, uncovers a nickel complex as an effective inhibitor of the 19S proteasomal DUBs and suggests a potentially new strategy for cancer treatment.

AB - Based on the central role of the ubiquitin-proteasome system (UPS) in the degradation of cellular proteins, proteasome inhibition has been considered an attractive approach for anticancer therapy. Deubiquitinases (DUBs) remove ubiquitin conjugates from diverse substrates; therefore, they are essential regulators of the UPS. DUB inhibitors, especially the inhibitors of proteasomal DUBs are becoming a research hotspot in targeted cancer therapy. Previous studies have shown that metal complexes, such as copper and zinc complexes, can induce cancer cell apoptosis through inhibiting UPS function. Moreover, we have found that copper pyrithione inhibits both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that of the classical 20S proteasome inhibitor bortezomib. In the present study, we reveal that (i) nickel pyrithione complex (NiPT) potently inhibits the UPS via targeting the 19S proteasome-associated DUBs (UCHL5 and USP14), without effecting on the 20S proteasome; (ii) NiPT selectively induces proteasome inhibition and apoptosis in cultured tumor cells and cancer cells from acute myeloid leukemia human patients; and (iii) NiPT inhibits proteasome function and tumor growth in nude mice. This study, for the first time, uncovers a nickel complex as an effective inhibitor of the 19S proteasomal DUBs and suggests a potentially new strategy for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84964355530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964355530&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.114

DO - 10.1038/onc.2016.114

M3 - Article

C2 - 27086925

AN - SCOPUS:84964355530

VL - 35

SP - 5916

EP - 5927

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 45

ER -